Symptoms ‐ Long‐term improvement: > 3 months · carpal tunnel syndrome
1 finding from 1 review
Significant improvement in disability within 6 weeks · people with CIDP
Intravenous immunoglobulin leads to higher significant improvement in disability within 6 weeks compared with placebo (high certainty).
1 finding from 1 review
Change in mean disability score on Rankin scale · people with CIDP
1 finding from 1 review
Change in mean disability score at 24 weeks or later · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with prednisolone (moderate certainty).
1 finding from 1 review
Significant improvement in disability within 6 weeks · people with CIDP
Intravenous immunoglobulin showed no clear difference in significant improvement in disability within 6 weeks compared with intravenous methylprednisolone (moderate certainty).
1 finding from 1 review
Change in mean disability score on Rankin scale · people with CIDP
1 finding from 1 review
Change in mean disability score at 24 weeks or later · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with intravenous methylprednisolone (moderate certainty).
1 finding from 1 review
Change in mean disability score on Rankin scale · people with CIDP
1 finding from 1 review
Change in mean disability score at 24 weeks or later · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Significant improvement in disability within 6 weeks · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in mean disability score on Rankin scale · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in mean disability score at 24 weeks or later · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with CIDP
1 finding from 1 review
Significant improvement in disability within 6 weeks · people with CIDP
Intravenous immunoglobulin showed no clear difference in significant improvement in disability within 6 weeks compared with prednisolone (moderate certainty).
1 finding from 1 review
Quit at longest · individuals who smoke cigarettes and are admitted to a hospital for medical or surgical care
It is very uncertain whether smoking cessation counselling changes quit at longest compared with no smoking cessation counselling, grouped by intensity of intervention (very low certainty).
4 findings from 1 review
RR 1.52 [0.8, 2.89]
2 studies · 1417 participants
Very low
RR 1.27 [1.02, 1.58]
12 studies · 4432 participants
Moderate
RR 1.04 [0.9, 1.2]
7 studies · 4627 participants
Very low
Show 1 more finding
Pharmacotherapy + behavioural support vs neither · smoking cessation in hospitalised patients
Hospital‐only intervention leads to higher pharmacotherapy + behavioural support vs neither compared with intervention that continues after hospital discharge (high certainty).
1 finding from 1 review
Quitline referral vs control · smoking cessation in hospitalised patients
It is very uncertain whether telephone quitline referral changes quitline referral vs control compared with no treatment or usual care (very low certainty).
1 finding from 1 review